| MSD Merck Sharp & Dohme AG - OncoTICE, Pulver zur Herstellung einer Suspension zur intravesikalen Anwendung | | 52563 | | 01 | | OncoTICE | | Pulver zur Herstellung einer Suspension zur intravesikalen Anwendung | | L03AX03 | | BCG-Impfstoff | | 16.11.1994 | | |
| | Composition | | Praeparatio cryodesiccata: bacillus Calmette-Guérin (BCG) vivus attenuatum (TICE) 200 - 800 Million CFU, lactosum monohydricum, asparaginum monohydricum, acidum citricum monohydricum, dikalii phosphas anhydricus, magnesii sulfas heptahydricus, ammonii ferri citras, glycerolum, ammonii hydroxidum, zinci formicas, pro vitro. | | Packungsbestandteile | | Praeparatio cryodesiccata: | | | Pulver zur Herstellung einer Suspension zur intravesikalen Anwendung | | | | | | | | Principe actif | Concentr. |
|---|
| Bacillus Calmette-Guérin (Bcg) Vivus Attenuatum (Tice) | 200-800 |
| | BAG: Principe actif | Concentr. |
|---|
| Bacillus Calmette Guerin (Bcg, Tice) | 500 Mio U |
| | | | Agents auxilliaires |
|---|
| Acide Citrique Monohydre | | Ammonii Ferri Citras | | Ammonii Hydroxidum | | Asparaginum Monohydricum | | Dipotassium Phosphate Anhydre | | Glycerol | | Lactose Monohydrate | | Magnesium Sulfate Heptahydrate | | Million Cfu | | Zinci Formicas |
| |
| | numéro d'emballage | Taille des présentations | PEF | PP | Cat. | LS | Hors commerce (MedRef) |
|---|
| 038 | Flacon perforable | 97.53 | 122.50 | A | LS | Non |
|
|
